{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-003165","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.267612+00:00","generated_at":"2026-06-27T20:18:42.726186+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aligos halts ALG-010133 development after Phase 1 data show no meaningful HBsAg reduction","bullets":["Halted development of STOPS drug candidate ALG-010133 for chronic hepatitis B.","Phase 1 study showed no meaningful HBsAg reduction at projected efficacious dose of 400 mg.","Higher doses up to 600 mg unlikely to reach 1 log10 IU/mL HBsAg reduction threshold.","No dose-limiting safety findings; decision made jointly with Study Review Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-003165","json":"https://secwatch.observer/filing/0001193125-22-003165.json","markdown":"https://secwatch.observer/filing/0001193125-22-003165.md","text":"https://secwatch.observer/filing/0001193125-22-003165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312522003165/0001193125-22-003165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312522003165/d288360d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:18:42.726186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}